Previous reports mostly demonstrated ALK rearrangement frequencies of 3-5 % in unselected patient populations [47–49], 3–25 % in adenocarcinomas [50–53], and 33 % in highly selected patient populations (EGFR wild-type, female, non/light smokers) [8]. This evidence concerns the gene ALK and adenocarcinoma.